The global brain tumor treatment market is expected to garner a market value of US$ 3,114.2 million in 2023 and is expected to accumulate a market value of US$ 6,228.2 million by 2033, registering a CAGR of 7.2% in the forecast period. The rising prevalence of such cancer and the growing geriatric population are key drivers expected to nurture the growth of the brain tumor diagnosis market worldwide. The market for brain tumor treatment registered a CAGR of 4.7% in the historical period.
| Data Points | Key Statistics |
|---|---|
| Brain Tumor Treatment Market Value 2023 | US$ 3,114.2 million |
| Brain Tumor Treatment Market Projected Value (2033) | US$ 6,228.2 million |
| Brain Tumor Treatment Market CAGR (2023 to 2033) | 7.2% |
A brain tumor is an abnormal and uncontrolled proliferation of cells in the brain. It can be benign or malignant. Brain tumor arises from brain tissue and rarely spreads. The tumor eventually compresses and damages other structures in the brain. According to American Brain Tumor Association (ABTA), there are two types of brain tumors - primary and secondary. Primary tumors arise from brain tissue and secondary tumors arise from other parts of the body and spread to the brain.
Gliomas are the most common type of primary tumor which arises from the brain’s glial tissue. Glioblastoma multiform is fast-growing and of a higher grade when compared to other tumors. Advanced medications are available to treat brain tumors. Increasing pharmaceutical Research and Development spending is expected to provide lucrative growth for the global brain tumor treatment industry over the forecasted period.
Based on region, North America is estimated to capture the highest share owing to the advanced healthcare facilities and hefty investment in the research program to find an effective treatment for brain tumors.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for brain tumor treatment is projected to increase at a CAGR of 7.2% during the forecast period, reaching a total of US$ 6,228.2 million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 4.7%.
Over the years, accelerating research activities in the oncology sector and increasing adoption of advanced technologies for cancer treatment have augmented the demand for brain tumor therapeutics across the globe.
According to the Central Brain Tumor Registry of the USA (CBTRUS) statistical report of 2016, an estimated 79,270 new cases of primary malignant, non-malignant, and other CNS cancers were diagnosed in the United States in 2020 (26,070 primary malignant and 53,200 non-malignant). Thereby, the increasing prevalence of brain cancer cases across the globe is expected to propel the demand for brain tumor diagnosis/treatment throughout the forecast period.
Growing on Chemotherapies and Increasing Awareness to Act as Principal Growth Drivers
An increase in the prevalence rate of brain tumors has fueled the demand for effective treatment. For instance, as per the American Society of Clinical Oncology (ASCO), the brain tumor incidence rate growing by 2.6% compared to the last year. An estimated 22,850 cases are diagnosed with primary cancerous tumors of the brain in the United States. Furthermore, the increasing geriatric population is also driving the brain tumor market.
As such, global companies are spending a significant portion of their revenue on Research and Development to develop novel medications. Numerous products related to novel drug delivery technologies are lined up for FDA approval. Increasing demand for advanced medication to treat brain tumors is expected to fuel the overall growth of the market. Increasing consumer awareness regarding the latest technological advancements in therapies, and medications are responsible for the growth of the global brain tumor treatment market.
Principal Consultant
High Cost of Treatment May Hamper the Market Expansion of the Brain Tumor Treatment Market
Successfully treating brain tumors can be challenging. The body’s blood-brain barrier normally protects the brain and spinal cord from harmful chemicals. However, this barrier also keeps out many types of chemotherapy. Surgery can be difficult if the tumor is near a delicate part of the brain or spinal cord. Even when the surgeon can completely remove the original tumor, parts of the tumor may remain that are too small to be seen or removed during surgery. Radiation therapy can also damage healthy tissue.
However, research in the past 20 years has helped to significantly lengthen lives and improved the quality of life for many people with brain tumors. These advancements include more refined surgeries, a better understanding of which types of tumors respond to chemotherapy and other drugs, and more targeted delivery of radiation therapy. Besides, the higher initial cost of treatment and clinical trials may act as major roadblocks over the coming years.
Advanced Healthcare Infrastructure & Presence of Innovative Research Centers Nurture the Demand for Brain Tumor Treatment
| Region | North America |
|---|---|
| Market Share % (2022) | 34.2% |
North America region is expected to dominate the global brain tumor treatment market throughout the forecast period, owing to increasing incidences of glioblastoma coupled with technological advancements. North America is expected to account for more than 34.2% share of the global brain tumor treatment market in 2023. Advanced healthcare infrastructure, greater per capita healthcare spending, and comparatively higher awareness regarding advanced technologies are certain to impact rendering factors.
Besides, the presence of advanced healthcare facilities and innovative research centers is another reason for fueling the demand for brain tumor treatment & therapeutics. For instance, the UCSF Brain Tumor Center is one of the largest and most comprehensive programs in the region for the treatment of brain and spinal tumors. This center includes advanced intra-operative imaging and brain mapping techniques to protect areas of the brain used for language, motor skills, and sensory function during surgery, as well as radiosurgery with Gamma Knife and CyberKnife and access to clinical trials of promising new therapies.
Encouraging Healthcare Programs & Increasing Clinical Trials for Novel Drug Development to Spur Demand for Brain Tumor Treatment
| Region | Europe |
|---|---|
| Market Share % (2022) | 24.2% |
Europe is expected to contribute significantly to this space over the forecast period, which can be attributed to the increasing prevalence of malignant cancers in countries like the United Kingdom For instance, as per statistics provided by the Office for National Statistics, United Kingdom, in 2021, around 11,000 new cases were registered in the region.
Europe is the second largest in terms of market revenue and is estimated to witness significant gains throughout the forecast period. As per Future Market Insights, Europe is slated to account for a 21% share of the global brain tumor treatment market. This market growth is attributed to the increasing emphasis on cancer research and the rising prevalence of cancer cases in the region.
EANO is Europe’s multidisciplinary Neuro-Oncology organization representing all medical and scientific disciplines involved in the prevention, diagnosis, and treatment of tumors of the central nervous system (CNS). EANO is dedicated to promoting advances in Neuro-Oncology through innovative research and concerted education and training. Moreover, encouraging healthcare programs and the adoption of state-of-the-art technologies for the identification and treatment of malignant cancers in hospitals and healthcare facilities is likely to propel the brain tumor treatment market in the region.
Increasing Adoption of Cutting-edge Technology in Several Countries to Escalate the Market Growth of Brain Tumor Treatment
| Country | Market CAGR % (2023 to 2033) |
|---|---|
| China | 8.8% |
| India | 7.2% |
The Asia Pacific represents a significant share of the brain tumor treatment market and is projected to experience robust growth throughout the forecast period, states Future Market Insights report. A significant increase in the incidence rate of brain tumors along with the shifting of locus of economic activity and dynamism to this region is expected to boost the demand for drugs responsible for brain tumor treatment.
The development of novel drugs and increasing clinical trials have boosted the market growth of the brain tumor treatment market in the Asia Pacific region. Encouraging healthcare policies and smooth drug approval programs by FDA are other aspects driving the market for brain tumor treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 7.2% from 2023 to 2033 |
| Market Value in 2023 | US$ 3,114.2 million |
| Market Value in 2033 | US$ 6,228.2 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
The market is forecast to register a CAGR of 7.2% through 2033.
The market is valued to hit US$ 6,228.2 million by 2033.
The global market advanced at a 4.7% CAGR from 2018 to 2022.
The market is estimated to secure a valuation US$ 3,114.2 million in 2023.
In 2023, North America may command a 34.2% market share.
The projected global market share for Europe is 24.2%.
The China market to record a market CAGR of 8.8% through 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Temozolomide
5.3.2. Carmustine
5.3.3. Cisplatin
5.3.4. Bevacizumab
5.3.5. Geftinib
5.3.6. Erlotinib
5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Ambulatory Surgical Centers
6.3.3. Individual Pharmacies
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Product
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Product
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product
9.3.3. By End User
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Product
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By End User
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Product
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By End User
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Product
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product
13.2.3. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By End User
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Product
14.2.3. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Product
15.1.2.2. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Product
15.2.2.2. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Product
15.3.2.2. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Product
15.4.2.2. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Product
15.5.2.2. By End User
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Product
15.6.2.2. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Product
15.7.2.2. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Product
15.8.2.2. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Product
15.9.2.2. By End User
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Product
15.10.2.2. By End User
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Product
15.11.2.2. By End User
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Product
15.12.2.2. By End User
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Product
15.13.2.2. By End User
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Product
15.14.2.2. By End User
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Product
15.15.2.2. By End User
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Product
15.16.2.2. By End User
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Product
15.17.2.2. By End User
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Product
15.18.2.2. By End User
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Product
15.19.2.2. By End User
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Product
15.20.2.2. By End User
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Product
15.21.2.2. By End User
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Product
15.22.2.2. By End User
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Product
15.23.2.2. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product
16.3.3. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Genentech USA
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Bristol Myers Squibb
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Hoffmann- La Roche
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. AstraZeneca Plc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Pfizer Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Novartis AG
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Antisense Pharma
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Merck & Co
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. MacLeod’s Pharmaceutical Limited
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Mankind Pharma
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Siemens Healthineers AG
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Dr. Reddy’s Laboratories Ltd.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Brain Tumor Treatment Market
